Research questions new Medtronic stent

The Endeavor stent, which Medtronic hopes can hold on to a respectable chunk of the $4 billion worldwide stent market, leads to more complications than rival devices and doesn’t reduce the need for future treatment, according to research presented at a conference yesterday. But the researchers cautioned that the study patients have only been followed for nine months so far, and Endeavor may have been placed into patients who were sicker to start with. Report

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.